Drug
Emicizumab clinical trials
Also written Hemlibra, RO5534262 and ACE910.
- studies test it
- 26
- open now
- 8
- in phase 3
- 14
- first study started
- 2015
Keep track of what changes. Save the emicizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Hemlibra
- 17
Combined with it in one product
Studies by the year they started
26 studies that test it; most in 2021 (6)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 4
- Phase 3
- 14
- Phase 4
- 7
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 13
Hoffmann-La Roche (11) · Indiana Hemophilia &Thrombosis Center, Inc. (2) · Margaret Ragni (2) · University of Washington (1) · GWT-TUD GmbH (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Versiti Blood Health (1) · Dhaka Medical College (1)
Often tested with
Tested in the same studies.
Preventive Intervention (1) · Fitusiran (1) · Anti-inhibitor coagulant complex (1) · Factor VIII-Fc fusion protein (1) · BAX 855 (1)
Studies
Open first, then newest update. How each study uses emicizumab is read from its arms, and is right about nine times in ten.
Testing it · 26
- A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand DiseaseRecruitingPhase 3Hoffmann-La RocheNCT06998524Written as Emicizumab
- A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With EmicizumabRecruitingPhase 4SanofiNCT06145373Written as Emicizumab
- SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisRecruitingPhase 3Emory UniversityNCT04563520Written as Emicizumab
- Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance InductionNot yet recruitingPhase 4Versiti Blood HealthNCT07158606Written as Emicizumab
- Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia ARecruitingPhase 1Bleeding and Clotting Disorders Institute Peoria, IllinoisNCT05500807Written as Emicizumab
- Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A PatientsNot yet recruitingPhase 2/3Dhaka Medical CollegeNCT06938659Written as Emicizumab Injection
- Hemlibra in Mild Hemophilia ARecruitingPhase 4Indiana Hemophilia &Thrombosis Center, Inc.NCT04567511Written as Emicizumab
- Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia ARecruitingPhase 2/3Chulalongkorn UniversityNCT06155955Written as "Emicizumab", "HEMLIBRA®"
- A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab ProphylaxisActive, not recruitingPhase 4Hoffmann-La RocheNCT05181618Written as Emicizumab
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without InhibitorsActive, not recruitingPhase 3Hoffmann-La RocheNCT04431726Written as Emicizumab
- A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII InhibitorsCompletedPhase 3Hoffmann-La RocheNCT04158648Written as Emicizumab
- POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement TherapiesWithdrawnPhase 4University of Texas Southwestern Medical CenterNCT04690322Written as Emicizumab
- Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A ParticipantsCompletedPhase 3Hoffmann-La RocheNCT03315455Written as Emicizumab
- Emicizumab in Patients With Acquired Hemophilia AActive, not recruitingPhase 2University of WashingtonNCT05345197Written as emicizumab
- HemLibra Prophylaxis in Patients With Hemophilic PseudotumorTerminatedPhase 4Indiana Hemophilia &Thrombosis Center, Inc.NCT03921294Written as Emicizumab
- The Hemophilia Inhibitor Prevention TrialTerminatedPhase 3Margaret RagniNCT04303559Written as Emicizumab Injection [Hemlibra]
- The Hemophilia Inhibitor Eradication TrialTerminatedPhase 3Margaret RagniNCT04303572Written as Emicizumab
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia ACompletedPhase 3Hoffmann-La RocheNCT03020160Written as Emicizumab
- Emicizumab in Acquired Hemophilia ACompletedPhase 2GWT-TUD GmbHNCT04188639Written as Emicizumab Injection
- A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without InhibitorsCompletedPhase 3Hoffmann-La RocheNCT02847637Written as Emicizumab
See all 26 studies that test emicizumab →
Given in every arm · 2 — emicizumab is usual care beside what is tested
As the comparator · 1 — what is tested is compared with emicizumab
Codes
What other systems call emicizumab · ClinicalTrials.gg INT000473
- MeSH (NLM) C000608208emicizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7NL2E3F6K3EMICIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1989794Confirmed FDA, Wikidata
- Wikidata Q27155409emicizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C159541EmicizumabOne source FDA
- DrugBank DB13923One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000608208 | emicizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7NL2E3F6K3 | EMICIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1989794 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27155409 | emicizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C159541 | Emicizumab | One source FDA |
| DrugBank | DB13923 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.